On May 22, 2020, Ma, Xiaodong; Wang, Changyuan; Sun, Xiuli; Chen, Lixue; Zheng, Xu; Liu, Kexin; Xu, Jiawen; Li, Yanxia; Ai, Min; Chi, Fuyun published a patent.Recommanded Product: N-(3-Aminophenyl)acrylamide The title of the patent was Thiazolopyrimidine heterocyclic compound, composition and use thereof in treatment of lymphocytic leukemia. And the patent contained the following:
The present invention provides a thiazolopyrimidine heterocyclic compound, a composition and use thereof in preparation of drugs for treatment of lymphocytic leukemia. The thiazolopyrimidine heterocyclic compound is specifically a compound as represented in general formula I and II, wherein X is NH or O; R1 is H, Cl, Me, F, or OMe. The present invention further provides a use of the compound as represented in general formula I and II or pharmaceutically acceptable salts thereof or of a pharmaceutical composition containing same in treatment of tumor diseases by means of inhibiting JAK3 tyrosine kinase, in particular in preparation of drugs for treatment of Burkitt’s lymphoma, diffuse large B-cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Recommanded Product: N-(3-Aminophenyl)acrylamide
The Article related to thiazolopyrimidine heterocyclic preparation antitumor jak lymphoma leukemia, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: N-(3-Aminophenyl)acrylamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics